{"id":"ly3819253","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GLP-1 receptor agonists enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety through central nervous system effects. LY3819253 is being developed as a next-generation GLP-1 agonist, potentially with improved pharmacokinetics or efficacy compared to existing agents in this class.","oneSentence":"LY3819253 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:54.178Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT04518410","phase":"PHASE2, PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":"Coronavirus, Covid19","enrollment":4044},{"nctId":"NCT04427501","phase":"PHASE2, PHASE3","title":"A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-06-17","conditions":"COVID-19","enrollment":3307},{"nctId":"NCT05780268","phase":"PHASE3","title":"LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-05","conditions":"COVID-19","enrollment":314},{"nctId":"NCT04603651","phase":"","title":"Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Eli Lilly and Company","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04501978","phase":"PHASE3","title":"ACTIV-3: Therapeutics for Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-04","conditions":"Covid19","enrollment":2753},{"nctId":"NCT04634409","phase":"PHASE2","title":"A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-29","conditions":"COVID-19","enrollment":1755},{"nctId":"NCT04497987","phase":"PHASE3","title":"A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-08-02","conditions":"COVID-19, SARS-CoV2","enrollment":1180},{"nctId":"NCT04537910","phase":"PHASE1","title":"A Study of LY3819253 (LY-CoV555) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-09-02","conditions":"Healthy","enrollment":25},{"nctId":"NCT04701658","phase":"PHASE2","title":"A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-02-01","conditions":"COVID-19","enrollment":109},{"nctId":"NCT04411628","phase":"PHASE1","title":"A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-05-28","conditions":"COVID-19","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY-CoV555","Bamlanivimab"],"phase":"phase_3","status":"active","brandName":"LY3819253","genericName":"LY3819253","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY3819253 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}